Nanoparticle complexes of paclitaxel, bevacizumab, and albumin

Patent metadata

Field	Value
Publication number	US-2017196833-A1
Application number	US-201715413257-A
Country	US
Kind code	A1
Filing date	Jan 23, 2017
Priority date	Oct 1, 2012
Publication date	Jul 13, 2017
Grant date	—

Abstract

Described are nanoparticle complexes comprising paclitaxel, albumin and anti-HER2 antibody. The nanoparticle complexes are suitable for the treatment of cancer, in particular cancer that expresses VEGF.

First claim

1 . (canceled)

2 . An antibody-albumin nanoparticle complex comprising albumin, bevacizumab, and a therapeutically effective amount of paclitaxel, wherein the nanoparticle complex has been pre-formed in vitro by mixing an aqueous albumin-paclitaxel nanoparticle with bevacizumab under conditions to form the nanoparticle complex, such that bevacizumab retains anti-VEGF binding specificity, said complex having a diameter of less than 1 μm.

3 . The antibody-albumin nanoparticle complex of claim 2 , wherein the antibody binds an antigen expressed by a tumor cell.

4 . The antibody-albumin nanoparticle complex of claim 3 , wherein the tumor cell is a solid tumor cell.

5 . The antibody-albumin nanoparticle complex of claim 3 , wherein the tumor cell is derived from a colorectal cancer, a lung cancer, a glioblastoma, a kidney cancer, a cervical cancer, or an ovarian cancer.

6 . The antibody-albumin nanoparticle complex of claim 1 , wherein said nanoparticle complex comprises an alkylating agent.

7 . The antibody-albumin nanoparticle complex of claim 6 , wherein said alkylating agent is a platinum compound.

8 . The antibody-albumin nanoparticle complex of claim 7 , wherein said platinum compound is carboplatin.

9 . A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of antibody-albumin nanoparticle complexes, wherein said antibody-albumin nanoparticle complexes comprise albumin, bevacizumab, and a therapeutically effective amount of paclitaxel, wherein the nanoparticle complexes have been pre-formed in vitro by mixing albumin-paclitaxel nanoparticles with bevacizumab under conditions to form the nanoparticle complexes, such that bevacizumab retains anti-VEGF binding specificity, wherein the average diameter of at least 90 percent of said complexes is less than 1 μm.

10 . The pharmaceutical composition of claim 9 , wherein the antibody binds an antigen expressed by a tumor cell.

11 . The pharmaceutical composition of claim 10 , wherein the tumor cell is derived from a colorectal cancer, a lung cancer, a renal cell carcinoma, a cervical cancer, a skin cancer, or an ovarian cancer.

12 . The pharmaceutical composition of claim 9 , wherein said composition or said nanoparticle complexes comprise an alkylating agent.

13 . The pharmaceutical composition of claim 12 , wherein said alkylating agent is a platinum compound.

14 . The pharmaceutical composition of claim 13 , wherein said platinum compound is carboplatin.

Assignees

• Mayo Foundation

Inventors

• Markovic Svetomir N
• Nevala Wendy K

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61K47/6851

  the antibody targeting a determinant of a tumour cell · CPC title

• A61K31/337 Primary

  having four-membered rings, e.g. taxol · CPC title

• C07K16/2893

  against CD52 · CPC title

• A61K47/6867

  the tumour determinant being from a cell of a blood cancer · CPC title